Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. - Wikidata - wikimedia - TriplyDB

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

http://www.wikidata.org/entity/Q34682233

about

Vitamin B and its derivatives for diabetic kidney disease Does accumulation of advanced glycation end products contribute to the aging phenotype?Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease Present and future in the treatment of diabetic kidney disease Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets Carbonylation contributes to SERCA2a activity loss and diastolic dysfunction in a rat model of type 1 diabetes Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles.Dietary interventions to contrast the onset and progression of diabetic nephropathy: A critical survey of new data.Emerging drugs for diabetic retinopathy.Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging.Diabetic nephropathy - complications and treatment.Emerging drugs for chronic kidney disease.Risk for ESRD in type 1 diabetes remains high despite renoprotection.Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues Pyridoxamine protects protein backbone from oxidative fragmentation.Advanced glycation end products facilitate bacterial adherence in urinary tract infection in diabetic mice.Pyridorin in type 2 diabetic nephropathy.Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.Role of advanced glycation end products in cardiovascular disease.Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths.Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women Inhibition of Advanced Glycation End Products (AGEs) Accumulation by Pyridoxamine Modulates Glomerular and Mesangial Cell Estrogen Receptor α Expression in Aged Female Mice.Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice Carbonylation induces heterogeneity in cardiac ryanodine receptor function in diabetes mellitus.Pyridoxamine protects proteins from damage by hypohalous acids in vitro and in vivo.Implications of treatment that target protective mechanisms against diabetic nephropathy Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of Human Type 2 Diabetic Nephropathy Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults 5'-O-Alkylpyridoxamines: Lipophilic Analogues of Pyridoxamine Are Potent Scavengers of 1,2-Dicarbonyls.Pretreatment with pyridoxamine mitigates isolevuglandin-associated retinal effects in mice exposed to bright light.Advanced glycation end products (AGE) and diabetes: cause, effect, or both?Glycation in diabetic nephropathy.Oxidative stress in early diabetic nephropathy: fueling the fire.Antifibrotic treatment and other new strategies for improving renal outcomes New approaches to the treatment of nephropathy in diabetes.Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.

P2860

Q24186641-43865811-FA30-4930-A693-D2AC0B48730F Q24632710-EFFDAC89-9DEF-42F4-928B-292BE883E971 Q24658195-3964F0EB-1A3E-450F-BEED-7DFE937C9350 Q26782422-48CB22F2-2912-4510-84A7-B3DB803E9103 Q26864133-3103CA8A-F023-48CB-B6CD-1D545576B28F Q28086840-BBADD7CD-E528-4207-A91A-3CA4FB49F328 Q28577628-52D20B5E-B8DE-4AEF-8A87-BBB2BCE31D66 Q30407920-29423997-3BDC-45C5-AD44-354D3718927B Q31157315-0FB907A8-941C-4D19-A2EE-5FA03EB725BC Q33388498-06EA6D9B-AAD8-4C41-A7F8-33589C83679B Q33691339-766006FA-9731-4866-BCB9-64D541308070 Q34387952-C7CFA425-B1B6-4D1D-988F-3B4275947463 Q34420383-1A5DC66B-E6D9-4A2A-A0DA-9B7AFAD22EA6 Q34695426-6C74EBC1-1CAD-43DB-A6DF-C8087ACF86F3 Q35118391-B2B80CDD-A99B-460A-BA0D-89FC060C3FEA Q35155529-17824F9B-A8A7-4ED7-8C47-016025489AFA Q35647771-BFEB1E47-E82F-4B18-BCFE-2C4E6FB9DE1E Q35720807-B4911398-CC60-4ED9-BA2A-52636C5EA772 Q35809946-ACB3FF25-A813-4671-A6A2-910CD87CEB69 Q35896615-5C8374CC-DC4B-4C04-BD00-846FDEA168B7 Q35929112-0F5637FD-6154-4FC3-A739-66DC5F8F9323 Q35953867-E16A41EE-FC88-462D-9AD8-B9492A988E68 Q35995060-AAEE9B1D-0B6C-4A02-B043-08DDB1D2264B Q36047141-32DC7881-7590-4F4B-A053-EFD53655BD0E Q36080001-CA3AF493-448D-49B4-A042-56527E04E7FD Q36109288-43F2A568-05AB-490F-B161-33A0AC690031 Q36174773-3B5009DD-58E4-44DB-95DA-ABE71488A6F2 Q36386384-EA55E10C-69BC-44D0-AFE2-9DC0658D9AAB Q36645971-4614487B-DA62-4134-8A09-8F481010F816 Q36734406-E12EB70A-D288-455C-8360-7AD5AAA8C830 Q37088388-A4B8BCEB-7BBF-44C6-A230-DB552E6DCC94 Q37088397-F219970F-3129-4D00-A3CC-36718242FD84 Q37200477-5B7AB46C-FDB1-4FCC-B3E8-7E594C7EA158 Q37226073-37DDCA42-12E9-4486-84DE-938C66D03492 Q37520014-55FF48CD-02BD-4F98-96AB-69FD85514AA2 Q37801858-E8A20C27-613E-477B-9865-A004C2B110A1 Q37820092-64FA5CDE-6632-4A04-A359-8A5E2F85584A Q37887401-E7AC89BE-0F49-4F09-9261-E6AA3CABD8CF Q37899907-93154F51-6405-4A94-A0D3-3BC0E2877BF2 Q37959165-BE82CE4C-E5BE-49A8-A8B5-646BD3D81E07

P2860

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

http://www.wikidata.org/entity/Q34682233

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@ast

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@en

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@nl

type

label

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@ast

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@en

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@nl

prefLabel

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@ast

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@en

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@nl

P1433

Q34682233-3F8F6FB1-EE77-490E-8F4D-C601C1A8C344

P1476

Q34682233-255AE261-AF03-4F98-B9DD-A765E1391696

P2093

Q34682233-03B08500-8D8F-47C2-97C7-B6721DFE9C76

Q34682233-1BF5751D-D780-47E9-8D5E-14127749CB96

Q34682233-4D929768-8F82-4738-B7A0-45C9F6F76005

Q34682233-616AC677-7BE4-4BA8-BFA9-6BAC077FF056

Q34682233-6BA4119A-D117-464B-8568-1507CAAD91A4

Q34682233-BA231196-B567-43CD-860A-A50446540E06

P2860

Q34682233-01251DF7-6C97-43B5-9C15-00163C9A070A

Q34682233-093B59D1-80F2-44C8-8E88-F2AD37C6E51B

Q34682233-318A3321-260C-4F15-95BA-BBA8B475827B

Q34682233-5333C35C-B124-46C4-AF67-8C665407AB79

Q34682233-6389C710-E7C4-4F0A-9743-272D376AD4CE

Q34682233-66879141-3246-4B62-84B5-A39448D8E4D5

Q34682233-6E0C5EC9-2A76-4750-AA1F-8A9E6396114A

Q34682233-6F54425F-1A63-4092-8B1F-79A68C293478

Q34682233-73F0F4E7-226F-4132-A662-7D3688A66EBF

Q34682233-7DF476D0-2E11-4675-B3CD-D367436EEFE3

P304

Q34682233-2E3C33BD-E3B1-4151-A0B7-CC5903A31F2F

P31

Q34682233-D4AAD727-19D3-4049-B5DD-E2AD54ACE096

P356

Q34682233-76401CEC-E8D2-4D6B-9294-8323A2B80DF5

P433

Q34682233-E7A814C1-BA09-403E-8D8B-91971AE8EE06

P478

Q34682233-E8856F1B-A23C-4D4D-B033-52B0C504DB1E

P577

Q34682233-CECE9C87-2A4C-426E-8BF1-0E17E56E33CD

P698

Q34682233-3E4B6BC5-267E-426F-A1CF-564AF16AF83C

P921

Q34682233-18783599-BFC7-4F66-AE41-B5203C069882

Q34682233-217282B5-7AF6-4943-864F-7AD98697E2C9

Q34682233-27430B8C-22FE-48CA-A970-3B5875162DDB

P356

P1433

American Journal of Nephrology

P1476

Effects of pyridoxamine in com ...... iabetes and overt nephropathy.

@en

P2093

Janet B McGill

http://www.w3.org/2001/XMLSchema#string

Mark E Williams

http://www.w3.org/2001/XMLSchema#string

Raja G Khalifah

http://www.w3.org/2001/XMLSchema#string

Robert J Schotzinger

http://www.w3.org/2001/XMLSchema#string

Thorsten P Degenhardt

http://www.w3.org/2001/XMLSchema#string

W Kline Bolton

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Biochemistry and molecular cell biology of diabetic complications

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

Advanced protein glycosylation in diabetes and aging.

Diabetes and nephropathy.

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

P304

605-614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000108104

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17823506

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

type-2 diabetes